Skip to main content
Download PDF

Correction to: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Arthritis Research & Therapy volume 22, Article number: 162 (2020) Cite this article

The Original Article was published on 22 February 2020

Correction to: Arthritis Res Ther (2020) 22:36

https://doi.org/10.1186/s13075-020-2124-3

Following publication of the original article [1], the authors identified two errors of referencing in the Discussion.

In the first paragraph of the Discussion, previous references 19–21 are incorrectly used twice and should be replaced with new references 36–38 and added to the reference list as follows:

36. Bingham CO, 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74.

37. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111.

38. Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171.

In the fifth paragraph, reference 15 is incorrectly used twice, and should be replaced with reference 9.

The authors sincerely apologize to the readers for any confusion caused by the errors.

Reference

  1. Nived P, Jönsson G, Settergren B, et al. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. Arthritis Res Ther. 2020;22:36 https://doi.org/10.1186/s13075-020-2124-3.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Central Hospital Kristianstad, J A Hedlunds väg 5, SE-291 85, Kristianstad, Sweden

    Per Nived & Bo Settergren

  2. Department of Clinical Sciences Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden

    Per Nived, Jon Einarsson, Tor Olofsson & Meliha C. Kapetanovic

  3. Department of Clinical Sciences Lund, Section of Infectious Diseases, Lund University and Skåne University Hospital, Lund, Sweden

    Göran Jönsson

  4. Department of Microbiological Diagnostics & Virology, Statens Serum Institut, Copenhagen, Denmark

    Charlotte Sværke Jørgensen

  5. Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund, University, Lund and Clinical Immunology and Transfusion Medicine, Region Skåne, Lund, Sweden

    Lillemor Skattum

Authors
  1. Per Nived
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Göran Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo Settergren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jon Einarsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tor Olofsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charlotte Sværke Jørgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lillemor Skattum
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Meliha C. Kapetanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per Nived.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nived, P., Jönsson, G., Settergren, B. et al. Correction to: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. Arthritis Res Ther 22, 162 (2020). https://doi.org/10.1186/s13075-020-02256-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13075-020-02256-2

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us